Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DEVICE DEBUTS: Product And New Indication Launches From Medtronic, Strkyer, Siemens, And More

Executive Summary

This month's edition of Device Debuts includes new product launches from Medtronic, Cochlear, Qualcomm, Titan Spine, Stryker, Philips, Nuance, Nevro, Siemens, Vortex BioSciences, ResMed, Respircardia, and others.

You may also be interested in...



Medicare Bonus Payments: CMS Plans To End Three, But Considers Seven New-Tech Add-On Payments For FY 2019

While the US Medicare agency is proposing to end hospital inpatient new-technology add-on payments for Edwards Lifesciences’ and LivaNova’s minimally surgical valves, and for WL Gore's endoprosthesis aneurysm device, it is evaluating possible bonus payments for 7 more devices beginning Oct. 1.

Global Approvals Analysis: Eight Brain Device Approvals Mark Neurotech November

Medtech Insight's Approvals Tracker reports 22 medical device approvals from outside the United States in November, including 12 CE marks from Europe, plus approvals from Taiwan, Singapore, Japan, India, Canada, Australia and Argentina.

US FDA Approves First Telehealth Option To Remotely Program Cochlear Implants

FDA approved a PMA supplement to remotely program sessions for Cochlear Americas' Nucleus Cochlear Implant System, heralding the feature as the first programming telehealth option for the hearing implants.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT121786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel